SCHEMBL6685970

SCHEMBL6685970

CNC(=O)C(OC)c1cccc(C(F)(F)F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.49
▸ MEN1 O00255 3/20 0.48
▸ KMT2A Q03164 3/20 0.48
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ ALDH1A1 P00352 3/20 0.48
▸ POLB P06746 2/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ CES2 O00748 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ PNMT P11086 1/20 0.47
▸ LMNA P02545 4/20 0.46
▸ HTT P42858 1/20 0.46
▸ MAPT P10636 3/20 0.45
▸ GAA P10253 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ HTR1E P28566 1/20 0.44
▸ S1PR3 Q99500 1/20 0.44
▸ TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30117130 0.85 MEN1 (0.51) MEN1KMT2ASMN1; SMN2ALDH1A1POLB
SCHEMBL27671576 0.84 PPARG (0.53) KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL8370289 0.81 SMN1; SMN2 (0.56) KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL30645113 0.81 KMT2A (0.51) KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL8227131 0.79 MEN1 (0.50) KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL27690525 0.79 PNMT (0.49) MEN1KMT2ASMN1; SMN2ALDH1A1POLB
Tert-Butylamine SCHEMBL27690523 0.79 PPARG (0.49) KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL27690520 0.77 PNMT (0.47) MEN1KMT2ASMN1; SMN2ALDH1A1POLB
SCHEMBL8281830 0.76 ALDH1A1 (0.64) KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL13434151 0.76 ALDH1A1 (0.64) KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1461026-A2 METHOD FOR TREATING OCULAR HYPERTENSION Merck & Co., Inc. (US) 2004-09-29 — — EP disclosed
WO-2003047513-A2 METHOD FOR TREATING OCULAR HYPERTENSION MERCK & CO., INC. (US) 2003-06-12 — — WO disclosed
WO-2001046140-A1 EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS PFIZER PRODUCTS INC. (US) 2001-06-28 — — WO disclosed
Send feedback